Efficacy and safety of twice-daily pharmacokinetically enhanced amoxicillin/clavulanate (2000/125 mg) in the treatment of adults with community-acquired pneumonia in a country with a high prevalence of penicillin-resistant Streptococcus pneumoniae.
Siquier, B. 1; Sanchez-Alvarez, J. 2; Garcia-Mendez, E. 3; Sabria, M. 4; Santos, J. 5; Pallares, R. 6; Twynholm, M. 7; Dal-Re, R. 3,*; on behalf of the 620 Clinical Study Group
[Article] Journal of Antimicrobial Chemotherapy. 57(3):536-545, March 2006.

(Format: HTML, PDF)